The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The transcriptional regulator c-JUN is a key mediator of the metastatic potential and drug resistance in melanoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, c-JUN induces an EMT-like phenotype switch that may be responsible for the adaptive resistance to BRAF-MEK-ERK pathway inhibition in BRAFV600E melanoma cells [56].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [56]
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890 · cited 1×
“Functional category enrichment analysis using the NCBI Database for Annotation, Visualization and IntegratedDiscovery (DAVID) functional annotation toolwas used to identify GO terms (58) for the significant differentially expressed gene set.”
MethodSmyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196 · cited 2×
“These morphological and expression pattern alterations were consistent with previous descriptions of EMT programs in epithelial cancers (28) and of the phenotypic switch in melanoma (33).”
BackgroundResultImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationImproved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationCombined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Self-citationCombined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
Self-citationClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Self-citationSignaling mechanisms of the epithelial-mesenchymal transition
Gonzalez, D. M., & Medici, D. (2014) · Science Signaling · doi:10.1126/scisignal.2005189 · Cited by 1,721 · cited 1×
“ww Phenotype switching from a proliferative to invasive state in melanoma cells resembles the epithelial-mesenchymal transition (EMT) (28) associated with some epithelial cancers, often featuring changes in expression of specific markers such as E-cadherin to N-cadherin and activation of the transforming growth factor…”
BackgroundImproved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., Hamid, O., Infante, J. R., Millward, M., Pavlick, A. C., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60398-5 · Cited by 943
Self-citationReversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888
In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States
Hoek, K. S., Eichhoff, O. M., Schlegel, N. C., Döbbeling, U., Kobert, N., Schaerer, L., Hemmi, S., & Dummer, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2491 · Cited by 743
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730 · cited 1×
“A report showing that drug withdrawal restored responsiveness and intermittent dosing resulted in longer-termdrug responses (49) supports our findings that drug-induced effects provide a selective pressure for maintaining cells that are able to survive treatment.”
ResultlimmaGUI: A graphical user interface for linear modeling of microarray data
Wettenhall, J. M., & Smyth, G. K. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth449 · Cited by 722 · cited 1×
“Genes that were differentially expressed between the drug-resistant versus the drug-sensitive cell lines were identified using the “limma” algorithm (56, 57), having adjusted P values less than 0.”
MethodMorris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness
Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K. S., Testori, A., Larue, L., & Goding, C. R. (2006) · Genes & Development · doi:10.1101/gad.406406 · Cited by 608
Lito, P., Pratilas, C. A., Joseph, E. W., Tadi, M., Halilovic, E., Zubrowski, M., Huang, A., Wong, W. L., Callahan, M. K., Merghoub, T., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.009 · Cited by 562
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Rizos, H., Menzies, A. M., Pupo, G. M., Carlino, M. S., Fung, C., Hyman, J., Haydu, L. E., Mijatov, B., Becker, T. M., Boyd, S. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3122 · Cited by 547
Self-citationA Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O., Kim, J. W., Cooper, Z. A., Piris, A., Frederick, D. T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0424 · Cited by 535
A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma
Caramel, J., Papadogeorgakis, E., Hill, L., Browne, G. J., Richard, G., Wierinckx, A., Saldanha, G., Osborne, J., Hutchinson, P., Tse, G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.018 · Cited by 517
Self-citationCancer stem cells versus phenotype‐switching in melanoma
Hoek, K. S., & Goding, C. R. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00757.x · Cited by 506
Criteria for Analyzing Interactions between Biologically Active Agents
(1981) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60912-4 · Cited by 454
Resistance to BRAF-targeted therapy in melanoma
Sullivan, R. J., & Flaherty, K. T. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.019 · Cited by 374 · cited 1×
“Acquired resistance to BRAF and/or MEK inhibitors in most cases occurs through mechanisms that reactivate the ERK pathway, such as activating NRAS mutations, MEK mutations, BRAF amplification, alternative slicing of BRAF, or activation of receptor tyrosine kinases [reviewed in (9)].”
BackgroundJNK signalling in cancer: in need of new, smarter therapeutic targets
Bubici, C., & Papa, S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12432 · Cited by 346
Parmenter, T. J., Kleinschmidt, M., Kinross, K. M., Bond, S. T., Li, J., Kaadige, M. R., Rao, A., Sheppard, K. E., Hugo, W., Pupo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0440 · Cited by 283
Self-citationJönsson, G., Busch, C., Knappskog, S., Geisler, J., Miletic, H., Ringnér, M., Lillehaug, J. R., Borg, Å., & Lønning, P. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2509 · Cited by 283
Kirkwood, J. M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Middleton, M., Cantarini, M., Zazulina, V., Kemsley, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1491 · Cited by 278
O'Connell, M. P., Marchbank, K., Webster, M. R., Valiga, A. A., Kaur, A., Vultur, A., Li, L., Herlyn, M., Villanueva, J., Liu, Q., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0005 · Cited by 222
Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
Kemper, K., de Goeje, P. L., Peeper, D. S., & van Amerongen, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1174 · Cited by 216
Nomachi, A., Nishita, M., Inaba, D., Enomoto, M., Hamasaki, M., & Minami, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802325200 · Cited by 211
The Small GTP-Binding Protein RhoA Regulates c-Jun by a ROCK-JNK Signaling Axis
Marinissen, M. J., Chiariello, M., Tanos, T., Bernard, O., Narumiya, S., & Gutkind, J. S. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00153-4 · Cited by 209
Young, R. J., Waldeck, K., Martin, C., Foo, J. H., Cameron, D. P., Kirby, L., Do, H., Mitchell, C., Cullinane, C., Liu, W., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12228 · Cited by 206 · cited 1×
“lines (24) and identified 4 cell lines that were intrinsically drug-resistant (IC50 > 1 mM) (Fig.”
BackgroundSelf-citationWNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
Anastas, J. N., Kulikauskas, R. M., Tamir, T., Rizos, H., Long, G. V., von Euw, E. M., Yang, P.-T., Chen, H.-W., Haydu, L., Toroni, R. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70156 · Cited by 176
Self-citationPhenotype Switching in Melanoma: Implications for Progression and Therapy
Li, F. Z., Dhillon, A. S., Anderson, R. L., McArthur, G., & Ferrao, P. T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00031 · Cited by 163
Self-citationAP-1/c-Jun transcription factors: Regulation and function in malignant melanoma
Kappelmann, M., Bosserhoff, A., & Kuphal, S. (2014) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2013.10.003 · Cited by 162
Jayachandran, A., Anaka, M., Prithviraj, P., Hudson, C., McKeown, S. J., Lo, P.-H., Vella, L. J., Goding, C. R., Cebon, J., & Behren, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2164 · Cited by 139
Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
Ferrao, P. T., Bukczynska, E. P., Johnstone, R. W., & McArthur, G. A. (2012) · Oncogene · doi:10.1038/onc.2011.358 · Cited by 133
Self-citationCo-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
Kwong, L. N., Boland, G. M., Frederick, D. T., Helms, T. L., Akid, A. T., Miller, J. P., Jiang, S., Cooper, Z. A., Song, X., Seth, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78954 · Cited by 128
Hagiwara, S., Kudo, M., Nagai, T., Inoue, T., Ueshima, K., Nishida, N., Watanabe, T., & Sakurai, T. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.145 · Cited by 109
Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching
Eichhoff, O. M., Weeraratna, A., Zipser, M. C., Denat, L., Widmer, D. S., Xu, M., Kriegl, L., Kirchner, T., Larue, L., Dummer, R., et al. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00871.x · Cited by 100
Fallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1
Leeksma, O. C., van Achterberg, T. A. E., Tsumura, Y., Toshima, J., Eldering, E., Kroes, W. G. M., Mellink, C., Spaargaren, M., Mizuno, K., Pannekoek, H., et al. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.02921.x · Cited by 98
Requirement of c-Jun NH 2 -Terminal Kinase for Ras-Initiated Tumor Formation
Cellurale, C., Sabio, G., Kennedy, N. J., Das, M., Barlow, M., Sandy, P., Jacks, T., & Davis, R. J. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01122-10 · Cited by 95
Wang, J., Kuiatse, I., Lee, A. V., Pan, J., Giuliano, A. E., & Cui, X. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0221 · Cited by 89 · cited 1×
“Beyond melanoma, sustained JNK signaling promotes EMT, invasion, and survival of breast cancer cells by regulating ERK activity (52), and JNK activation has been reported to predict for poor response to sorafenib in hepatocellular carcinoma (53).”
BackgroundPlasticity of melanoma and EMT-TF reprogramming
Tulchinsky, E., Pringle, J. H., Caramel, J., & Ansieau, S. (2014) · Oncotarget · doi:10.18632/oncotarget.1662 · Cited by 67
Self-citationAdaptive resistance to RAF inhibitors in melanoma
Kugel, C. H., & Aplin, A. E. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12264 · Cited by 64
Eichhoff, O. M., Zipser, M. C., Xu, M., Weeraratna, A. T., Mihic, D., Dummer, R., & Hoek, K. S. (2010) · Melanoma Research · doi:10.1097/cmr.0b013e32833bd89e · Cited by 54
ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma
Smit, M. A., Maddalo, G., Greig, K., Raaijmakers, L. M., Possik, P. A., van Breukelen, B., Cappadona, S., Heck, A. J., Altelaar, A. M., & Peeper, D. S. (2014) · Molecular Systems Biology · doi:10.15252/msb.20145450 · Cited by 54
The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel
Behren, A., Anaka, M., Lo, P., Vella, L. J., Davis, I. D., Catimel, J., Cardwell, T., Gedye, C. A., Hudson, C., Stan, R., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12097 · Cited by 53
Long, G. V., Wilmott, J. S., Haydu, L. E., Tembe, V., Sharma, R., Rizos, H., Thompson, J. F., Howle, J., Scolyer, R. A., & Kefford, R. F. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12098 · Cited by 40
Self-citationEvaluation of molecular markers of mesenchymal phenotype in melanoma
Mikesh, L. M., Kumar, M., Erdag, G., Hogan, K. T., Molhoek, K. R., Mayo, M. W., & Slingluff, C. L. (2010) · Melanoma Research · doi:10.1097/cmr.0b013e32833fafb4 · Cited by 37
Post‐transcriptional regulation controlled by E‐cadherin is important for c‐Jun activity in melanoma
Spangler, B., Vardimon, L., Bosserhoff, A., & Kuphal, S. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00787.x · Cited by 35
ETS‐1/RhoC signaling regulates the transcription factor c‐Jun in melanoma
Spangler, B., Kappelmann‐Fenzl, M., Schittek, B., Meierjohann, S., Vardimon, L., Bosserhoff, A., & Kuphal, S. (2011) · International Journal of Cancer · doi:10.1002/ijc.26277 · Cited by 31
Kang, M.-I., Baker, A., Dextras, C., Cabarcas‐Petroski, S., Young, M. R., & Colburn, N. H. (2012) · Genes & Cancer · doi:10.1177/1947601912448820 · Cited by 30
Knirsh, R., Ben‐Dror, I., Spangler, B., Matthews, G. D., Kuphal, S., Bosserhoff, A., & Vardimon, L. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1196 · Cited by 26
Editorial: Cellular and Phenotypic Plasticity in Cancer
Ferrao, P. T., Behren, A., Anderson, R. L., & Thompson, E. W. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00171 · Cited by 15
Self-citationCellular and Phenotypic Plasticity in Cancer
Thompson, E., Anderson, R. L., Behren, A., & Ferrao, P. T. (2015) · Frontiers research topics · doi:10.3389/978-2-88919-662-3 · Cited by 5
Cited by
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218
Phenotype plasticity as enabler of melanoma progression and therapy resistance
Arozarena, I., & Wellbrock, C. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0154-4 · Cited by 381
The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer
Hammouda, M., Ford, A., Liu, Y., & Zhang, J. (2020) · Cells · doi:10.3390/cells9040857 · Cited by 284
“The JNK signaling pathway mediates a wide range of cellular processes, including cell proliferation, survival, and migration [4,18,19], as well as cell apoptosis, senescence, and stress responses [20,21] (Figure 2).”
BackgroundThe CRUK IMAXT Grand Challenge Team, O’Flanagan, C. H., Campbell, K. R., Zhang, A. W., Kabeer, F., Lim, J. L. P., Biele, J., Eirew, P., Lai, D., McPherson, A., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1830-0 · Cited by 269
Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 235
“Exposure of BRAF-mutant melanoma cells to MAPK inhibitors initially induces up-regulation of JNK/c-Jun signaling, a known regulator of EMT-related genes and of cell adhesion and ECM molecules (Liu et al, 2015; Ramsdale et al, 2015).”
Metadata
- Authors
- Ramsdale, R., Jorissen, R. N., Li, F. Z., Al-Obaidi, S., Ward, T., Sheppard, K. E., Bukczynska, P. E., Young, R. J., Boyle, S. E., Shackleton, M., Bollag, G., Long, G. V., Tulchinsky, E., Rizos, H., Pearson, R. B., McArthur, G. A., Dhillon, A. S., & Ferrao, P. T.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Plexxikon (United States) (US)
- The University of Sydney (AU)
- University of Leicester (GB)
- Melanoma Institute Australia (AU)
- Corresponding author
- Ramsdale, Rachel
- Jorissen, Robert N.
- Ferrao, Petranel T.
- ORCID
- Venue
- Science Signaling
- Published
- 2015-08-18
- Volume
- 8
- Issue
- 390
- Pages
- ra82-ra82
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2318400076
- Cited by
- 143
- References
- 63
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 8 · 2023: 10 · 2022: 11 · 2021: 14 · 2020: 18 · 2019: 22 · 2018: 15 · 2017: 18 · 2016: 14
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Locations
- Science Signaling (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Peter MacCallum Cancer Foundation
- CASS Foundation
- National Health and Medical Research Council of Australia (1042980)
- China Scholarships Council
- Cancer Therapeutics CRC
- Australian National Health and Medical Research Council
- Pfizer Australia
- Victorian Endowment for Science, Knowledge and Innovation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- c-Jun, BRAF inhibitor resistance, BRAF V600-mutant melanoma, epithelial-mesenchymal transition, mesenchymal phenotype, Sprouty4, LEF1, JNK, transcriptional cofactors, drug resistance, BRAF/MEK inhibitors, cell migration, cell death
- MeSH terms
- Animals, Humans, Melanoma, Membrane Proteins, Microscopy, Fluorescence, Nerve Tissue Proteins, Phenotype, Blotting, Western, Gene Expression Regulation, Neoplastic, Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, RNA Interference, Cell Line, Tumor, Tumor Burden, Protein Kinase Inhibitors, Intracellular Signaling Peptides and Proteins, JNK Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins B-raf, Interleukin Receptor Common gamma Subunit, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.